Literature for GS-9256 (S29.001 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2014
1. Barauskas,O., Corsa,A.C., Wang,R., Hluhanich,S., Jin,D., Hung,M., Yang,H., Delaney,W.E.4. and Schultz,B.E.
   Binding kinetics, potency, and selectivity of the hepatitis C virus NS3 protease inhibitors GS-9256 and vedroprevir
   Biochim Biophys Acta1840, 3292-3298. PubMed  Europe PubMed DOI  I
2012
2. Sheng,X.C., Casarez,A., Cai,R., Clarke,M.O., Chen,X., Cho,A., Delaney,W.E., Doerffler,E., Ji,M., Mertzman,M., Pakdaman,R., Pyun,H.J., Rowe,T., Wu,Q., Xu,J. and Kim,C.U.
   Discovery of GS-9256: a novel phosphinic acid derived inhibitor of the hepatitis C virus NS3/4A protease with potent clinical activity
   Bioorg Med Chem Lett22, 1394-1396. PubMed  Europe PubMed DOI  I
3. Zeuzem,S., Buggisch,P., Agarwal,K., Marcellin,P., Sereni,D., Klinker,H., Moreno,C., Zarski,J.P., Horsmans,Y., Mo,H., Arterburn,S., Knox,S., Oldach,D., McHutchison,J.G., Manns,M.P. and Foster,G.R.
   The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
   Hepatology55, 749-758. PubMed  Europe PubMed DOI  I